

CURRENT REPORT 43/2023

October 16, 2023

RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") announces that the Company will present the updated data from the Phase I/II trial of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the upcoming European Society for Medical Oncology Congress ("ESMO"), to be held October 20-24, 2023, in Madrid, Spain.

The primary objectives of the ongoing trial are to assess the safety, and tolerability and determine the recommended phase 2 dose.

- Abstract Title: "Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor, in patients with relapsed/refractory metastatic or advanced solid tumors."
- Poster Number: 6880 / 672P
- Session date and time: Monday, 23 October, 9:00 am – 5pm CEST

As of the data cutoff date on May 1, 2023, Ryvu has administered treatment to 30 patients with metastatic or locally advanced solid tumors recruited into 7 cohorts (75 – 375 mg of RVU120). At the time of analysis, 15 patients had undergone at least 1 response assessment, and 13 of them achieved radiologic stable disease (SD) according to RECIST 1.1 criteria. Notably, one patient with refractory pancreatic cancer exhibited a reduction of CA19.9 marker levels on three consecutive time points and maintained a radiologic SD after completing three cycles of treatment. Two (2) out of 15 evaluable patients had progressive disease. Pharmacodynamic profiling confirms a relevant level of target engagement at doses up to 375 mg.

There were no occurrences of dose-limiting toxicities (DLT), and the majority of adverse events (AEs) reported were of Grade 1 or 2. Ten (10) serious adverse events (SAEs) were reported in 6 patients, but none of them was considered related to study drug.

The study is currently ongoing to further optimize dosing.

Company informs that it will host a webinar on Monday, October 23, 2023, at 9:00 am CEST to discuss the RVU120 Development Plan. The webinar can be accessed by following this link: <https://ryvu.clickmeeting.com/ryvu-esmo-2023-results-ryvu120-development-plans/register>

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board